Movano (NASDAQ:MOVE) versus Nexeon Medsystems (OTCMKTS:NXNN) Head to Head Review

Nexeon Medsystems (OTCMKTS:NXNN) and Movano (NASDAQ:MOVE) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, risk, dividends, earnings, institutional ownership, analyst recommendations and valuation.

Analyst Ratings

This is a summary of current recommendations and price targets for Nexeon Medsystems and Movano, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nexeon Medsystems	0	0	0	0	0.00
Movano	0	0	1	0	3.00

Movano has a consensus target price of $30.00, suggesting a potential upside of 752.27%. Given Movano’s stronger consensus rating and higher possible upside, analysts plainly believe Movano is more favorable than Nexeon Medsystems.

Volatility & Risk

Nexeon Medsystems has a beta of 6.98, indicating that its stock price is 598% more volatile than the S&P 500. Comparatively, Movano has a beta of 0.18, indicating that its stock price is 82% less volatile than the S&P 500.

Earnings and Valuation

This table compares Nexeon Medsystems and Movano”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nexeon Medsystems	N/A	N/A	N/A	N/A	N/A
Movano	$852,000.00	27.27	-$29.28 million	($6.75)	-0.52

Nexeon Medsystems has higher earnings, but lower revenue than Movano.

Insider & Institutional Ownership

16.6% of Movano shares are held by institutional investors. 61.2% of Nexeon Medsystems shares are held by insiders. Comparatively, 13.4% of Movano shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Nexeon Medsystems and Movano’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nexeon Medsystems	N/A	N/A	N/A
Movano	N/A	-452.96%	-233.43%

Summary

Movano beats Nexeon Medsystems on 5 of the 9 factors compared between the two stocks.

About Nexeon Medsystems

Nexeon MedSystems Inc., a medical device company, develops, manufactures, and commercializes neurostimulation technology for the treatment of various neurological disorders through electrical stimulation of neural tissues. Its neurostimulation technology platform would provide treatment to patients in several neurostimulator markets, including deep brain stimulation, peripheral electrical nerve stimulation, sacral nerve stimulation, spinal cord stimulation, vagus nerve stimulation, and other neurostimulator markets. The company develops the Viant, a deep brain stimulation system for Parkinson's disease in the United States, as well as for Parkinson's disease, Essential Tremor, and Dystonia in Europe. Nexeon MedSystems Inc. was founded in 2015 and is based in Dallas, Texas.

About Movano

Movano Inc. engages in developing a platform to deliver healthcare solutions at the intersection of medical and consumer devices. The company is involved in the development of Evie Ring, which is a wearable designed specifically for women that combines health and wellness metrics comprises resting heart rate, heart rate variability (HRV), blood oxygen saturation (SpO2), respiration rate, skin temperature variability, period and ovulation tracking, and menstrual symptom tracking, as well as activity profile, including steps, active minutes and calories burned, sleep stages and duration, and mood tracking. It develops System-on-a-Chip (SoC) for blood pressure or continuous glucose monitoring (CGM) systems. The company was formerly known as Maestro Sensors Inc. and changed its name to Movano Inc. in August 2018. Movano Inc. was incorporated in 2018 and is based in Pleasanton, California.